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Abstract Metabolomics can be performed either as an
‘open profiling’ tool where the aim is to measure, usually in a
semi-quantitative manner, as many metabolites as possible or
perform ‘closed’ or ‘targeted’ analyses where instead a pre-
defined set of metabolites are measured. Targeted methods
can be designed to be more sensitive and quantitative and so
are particularly appropriate to systems biology for quantita-
tive models of systems or when metabolomics is performed
in a hypothesis driven manner to test whether a particular
pathway is perturbed. We describe a targeted metabolomics
assay that quantifies a broad range of over 130 metabolites
relevant to cardiac metabolism including the pathways of the
citric acid cycle, fatty acid oxidation, glycolysis, the pentose
phosphate pathway, amino acid metabolism, the urea cycle,
nucleotides and reactive oxygen species using tandem mass
spectrometry to produce quantitative, sensitive and robust
data. This assay is illustrated by profiling cardiac metabolism
in a lamin A/C (Lmna) mouse model of dilated cardiomy-
opathy (DCM). The model of DCM was characterised by
increases in concentrations of proline and methyl-histidine
suggestive of increased myofibrillar and collagen degrada-
tion, as well as decreases in a number of citric acid cycle
intermediates and carnitine derivatives indicating reduced
energy metabolism in the dilated heart. These assays could
be used for any other cardiac or cardiovascular disease in that
they cover central core metabolism and key pathways
involved in cardiac metabolism, and may provide a general
start for many mammalian systems.
Keywords Metabonomics  Tandem mass spectrometry 
Lamin A/C  Cardiac disease
1 Introduction
Metabolomics is the global profiling of the metabolic
composition of a cell, tissue, organism or biofluid and has
wide ranging applications in many fields including biology,
medicine, functional genomics, the pharmaceutical indus-
try, and agrochemicals (Nicholson et al. 1999; Fiehn 2002;
Goodacre et al. 2004; Mayr 2008; Griffin et al. 2011;
Heather et al. 2013). Mass spectrometry based approaches
are increasingly being used in metabolomics to provide a
snap shot of global metabolism in biological studies,
reflecting the sensitivity of the approach to detect a wide
range of different chemicals. The analyses can be separated
into two differing philosophies. Open profiling based
metabolomics are non-targeted approaches which aim to
measure as many metabolites as possible using an assay
that is a compromise for a wide ranging list of metabolites.
While popular in biomarker discovery studies [for example
(Hodson et al. 2007; Dunn et al. 2008; Zhang et al. 2012)]
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they are at best semi-quantitative, often performed with a
limited number of standards using mass analysers that are
prone to sensitivity drift but good at analysing a wide range
of metabolites. Limits of detection are reduced by both the
compromised nature of the assay (i.e. optimisation is per-
formed for a diverse range of chemicals) and the dynamic
range of the assay, although it should be noted that many
high resolution mass spectrometers can routinely achieve a
dynamic range of 104. Furthermore, open profiling tech-
niques necessitate the use of multivariate statistics, and for
mass spectrometry complex software based alignment tools
for analysing chromatographic domains and access to
detailed databases to aid structure elucidation if the user is
to consider the majority of the metabolites detected (Kind
et al. 2009; Wishart 2009; Tautenhahn et al. 2012).
Alternatively, targeted methods have increased in pop-
ularity, particularly in systems biology, systems medicine
and biomarker validation where quantification is important.
These methods target a limited number of metabolites,
often relying on triple quadrupole mass spectrometry, and
because of this targeting have improved limits of detection
and quantification compared with open profiling approa-
ches. Data analysis for these types of datasets is also
simplified as the user already knows what metabolites
should have been detected and can set up a specific pro-
cessing method for the assay which identifies metabolites
according to fragmentation pattern and retention time.
Such approaches have been used to model metabolism in
E. Coli (Bennett et al. 2009), follow metabolic changes in
myocardial infarction and insulin resistance/type 2 diabetes
(Lewis et al. 2008; Wang et al. 2011; Wang-Sattler et al.
2012) and perform genome wide association studies
(GWAS) (Gieger et al. 2008). To further enhance the
robustness and reliability of the method, chromatography
can be optimized prior to mass spectrometry analysis to
ensure the separation of isobaric species (for example, the
metabolites leucine and isoleucine) or species that frag-
ment in such a way that they resemble other species (for
example ATP may fragment under certain conditions to
resemble ADP or AMP in terms of the ions produced). In
this manuscript we detail a targeted analysis of cardiac
metabolism, that while appropriate to a range of cardiac
diseases we have tested on a mouse model of inherited
cardiomyopathies.
Inherited cardiomyopathies are diseases caused by a
single mutation of a gene that subsequently affects the
structure and function of the heart. Two common forms are
hypertrophic cardiomyopathies (HCM) where the heart
increases in size as a result of increased muscle wall
thickness and dilated cardiomyopathy (DCM) where the
increase in heart size is not accompanied by an increase in
wall thickness. The incidence rate of DCM is 1 in 2500,
and is the commonest cause of cardiac transplantation and
death for non-ischaemic heart failure in young adolescents
and adults (Taylor et al. 2006). Over 50 genes are involved
in HCM and DCM, producing heterogeneous phenotypes
for the diseases (Judge 2009). Furthermore, the observed
phenotypes are also complicated by the fact that these
mutations interact with the wider genome of the individual,
further increasing the heterogeneity of the disease. Cur-
rently, less than 1 % of those with familial DCM are
genotyped in part because of the large number of genes and
mutations involved. Thus, there is a clinical need for
biomarkers that can identify individuals with DCM and
HCM. In addition such biomarkers could be used to follow
treatment efficacy.
When designing a targeted metabolomics assay for an
inherited cardiomyopathy it should be noted that a number
of metabolic abnormalities have been previously associated
with both DCM and HCM. DCM has been associated with
the generation of reactive oxygen species (ROS), particu-
larly as a result of mitochondrial stress (Charniot et al.
2011; Kitajima et al. 2011; Lu et al. 2012). In the heart one
of the major anti-oxidants is glutathione, while ROS will
oxidize certain nucleotides and amino acids which can act
as surrogate markers of ROS damage (Stadtman and
Levine 2003). In addition alterations in substrate selection
(Taha and Lopaschuk 2007), and in particular altered fatty
acid b-oxidation have been reported in both DCM
(Feinendegen et al. 1995) and HCM (Nakamura et al.
2000), while mutations associated with 50 adenosine
monophosphate-activated protein kinase (AMPK), a master
regulator of metabolism, have been linked to a range of
cardiomyopathies including diabetic cardiomyopathy,
DCM and HCM (Dolinsky and Dyck 2006; Taha and
Lopaschuk 2007). The heart has a high rate of b-oxidation,
and the carnitine shuttle transports fatty acids into the
mitochondria across the inner mitochondrial membrane for
oxidation as acyl-carnitines. Thus, the measurement of
tissue acyl-carnitines can determine mitochondrial function
and substrate selection. Furthermore, phosphorylated
nucleotides represent both the energy status of the heart
(ATP, ADP and AMP), and important regulatory molecules
used to determine substrate selection (cAMP).
Both HCM and DCM ultimately progress to the failing
heart, and in this state it has been observed that there is a
switch from the adult isoforms of key metabolic enzymes
to the fetal isoforms (Razeghi et al. 2002). These enzymes
include glucose transporters and mitochondrial carnitine
palmitoyl transferase-1, with these changes responsible for
a decrease in fatty acid oxidation and an increase in gly-
colysis in the failing heart.
Here we describe a series of targeted assays for the
metabolic profiling of cardiac tissue. These assays are robust
in performance, and sensitive in terms of limit of detection
and quantitative. The assays target key metabolites involved
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in the core pathways involved in energy production in the
heart (citric acid cycle, glycolysis and b-oxidation), ROS to
monitor oxidative damage in the cell and protein turnover
(amino acids), providing analysis of over 130 metabolites in
total. We illustrate their use by examining the metabolic
alterations associated with Lmna knockout mouse (Sullivan
et al. 1999) compared with wildtype controls. Although
developed to profile tissue from DCM and HCM patients
and the associated animal models, these assays could be
used for other cardiac disorders, and may provide a useful
starting point for targeted mammalian metabolomics.
2 Materials and methods
2.1 Chemicals reagents and chromatography
columns
LC–MS grade solvents and mobile phase additives were
obtained from Sigma Aldrich (Gillingham, Dorset, UK).
All standards for optimisation and quantitation including
the [U–13C] succinate used as an internal standard were
also obtained from Sigma Aldrich with the exception of the
[U–13C, U–15N] glutamate and the mixed standard of eight
deuterated acyl carnitines that was obtained from Cam-
bridge Isotope Laboratories (Andover, MA, USA). The
ZIC-HILIC sulfo betaine column was obtained from VWR
(Radnor, PA, USA), the Synergi Polar RP column from
Phenomenex (Torrance, CA, USA) and the HSS T3 column
from Waters (Milford, MA, USA).
2.2 Animals
Lmna knockout mice on a C57BL6/J background were
obtained from a stable colony at the Academic Medical Center
in Amsterdam which was generated from a previously
described mouse model (Sullivan et al. 1999). For genotyping,
genomic DNA was isolated from mice toe biopsies and
analysed by PCR. Mutant mice and wild type littermates
(C57BL6/J) were studied according to protocols approved by
the institutional Animal Ethics Committee at Acadamic
Medical Center Amsterdam. All animal experiments were
performed in accordance with Dutch law on care and use of
experimental animals. Lmna homozygous, heterozygous and
wildtype male mice were killed at the ages of 2, 5 and
40 weeks (n = 8 per experimental group). Hearts were
quickly harvested, rinsed in PBS, snap frozen in liquid nitro-
gen and stored at -80 C until extraction of metabolites.
2.3 Extraction of metabolites from heart tissue
Metabolites were extracted using the methanol/chloroform
method described by Le Belle et al. (2002). In brief 50 mg
of frozen heart tissue was ground with dry ice in a pestle
and mortar and placed inside 2 ml flat-bottomed screw cap
tubes. 600 ll of ice cold 2:1 methanol:chloroform was
added. After the addition of stainless steel balls, the sam-
ples were put into a tissue lyser (Qiagen, Hilden, Germany)
for 10 min at 25 Hz to ensure optimum extraction. 200 ll
of water and 200 ll of chloroform were added and the
samples thoroughly vortexed before centrifugation at
13,200 rpm for 25 min. After centrifugation the aqueous
(top layer) and organic (bottom layer) fractions were sep-
arated and aliquoted into separate tubes. A further 600 ll
of 2:1 methanol: chloroform was added to the original tube
and the extraction repeated as above. The aqueous and lipid
extracts were dried under nitrogen at room temperature for
about 3 h in a fume hood. Both were stored at -20 C
prior to analysis.
2.4 Instrumentation and mass spectrometry
parameter optimisation
All analyses were carried out using a Quattro Premier XE
quadrupole mass spectrometer coupled to an Acquity ultra
performance liquid chromatography (UPLC) system from
Waters Ltd. (Atlas Park, Manchester, UK). Compounds
were optimised for tandem MS analysis by preparing
individual standard solutions at 1 lM in the running buffer
for the relevant chromatographic assay, and directly
infused for parameter optimisation. Optimum mass spec-
trometry parameters and mass transitions were obtained by
using the automatic optimisation protocols of MassLynxTM
(Version 1.4, Waters) and for situations where no standards
were available, mass transitions and mass spectrometry
parameters were inferred from the parameters of known
analogues.
2.5 Analysis of HILIC mode polar compounds
measured in positive ion mode including
nucleotides and acyl CoAs
One half of the aqueous extract was dissolved in 150 ll of
70:30 acetonitrile:water containing 20 lM deoxy-glucose 6
phosphate and 20 lM [U–13C, 15N] glutamate. The
resulting solution was vortexed, then sonicated for 15 min
followed by centrifugation at 15,000 rpm with a bench top
centrifuge to pellet any remaining undissolved material.
The supernatant was transferred into a 300 ll vial (Agilent,
Santa Clara, CA, USA) and capped ready for analysis. For
chromatography on the UPLC system, the strong mobile
phase (A) was 100 mM ammonium acetate, the weak
mobile phase was acetonitrile (B) and the LC column used
was the ZIC-HILIC column from Sequant
(100 mm 9 2.1 mm, 5 lm). The following linear gradient
was used: 5 % A in acetonitrile was increased to 50 % A
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over 12 min with re-equilibration for a further 3 min. The
total run time was 15 min, the flow rate was 0.3 ml/min
and the injection volume was 2 ll. The metabolites were
separated into two functions consisting of 32 and 11 MRMs
owing to software limitations governing the number of
MRMs allowed per function. Mass spectrometry parame-
ters were the following: positive ion mode, a desolvation
temperature of 300 C, a source temperature of 110 C, an
ion spray voltage of 3.5 kV and a dwell time of 10 ms for
each analyte. Compound specific parameters such as cone
voltage and collision energy are listed in Table 1.
2.6 Analysis of HILIC mode polar compounds
measured in negative ion mode including
glycolytic intermediates and TCA cycle
intermediates
The sample from the positive ion mode analysis was
recovered and analysed in a second UPLC chromatography
assay. The strong mobile phase (A) was 10 mM ammo-
nium acetate with 0.05 % ammonium hydroxide and the
weak mobile phase was acetonitrile (B), and the LC col-
umn used was a BEH amide HILIC column
(100 9 2.1 mm, 1.7 lm; Waters Ltd). The following linear
gradient was used: 30 % A was held for 2 min followed by
a linear gradient to 50 % A at 7 min with further re-equi-
libration for 3 min, the total run time was 10 min. Mass
spectrometry parameters were the following: negative ion
mode, a desolvation temperature of 300 C, a source
temperature of 110 C, an ion spray voltage of 3.0 kV and
a dwell time of 10 ms for each analyte. Compound specific
parameters such as cone voltage and collision energy were
optimised according to the protocol above and are listed in
Table 1. Several compounds ionised in both positive and
negative mode and so were included in both types of
HILIC analyses.
2.7 Analysis of amino acids
The remaining sample from the HILIC analysis was thor-
oughly dried under nitrogen and derivatised with 200 ll of
3 M HCl in BuOH for 15 min at 65 C. After further
drying, the sample was reconstituted in 9:1 0.1 % formic
acid in water/acetonitrile and sonicated to ensure solvation
of the amino acid derivatives. Samples were analysed on
the UPLC interfaced with the triple quadrupole LC–MS/
MS. The strong mobile phase used for analysis was ace-
tonitrile (B) and the weak mobile phase was 0.1 % formic
in water (A). The analytical UPLC gradient used a HSS T3
column (100 mm 9 2.1 mm, 1.7 lm) from Waters Ltd
with 5 % B in 0.1 % formic acid at 0 min followed by a
linear gradient to 40 % B after 7 min and another gradient
to 100 % B at 10 min followed by re-equilibration for
3 min. The total run time was 13 min and the flow rate was
0.5 ml/min with an injection volume of 2 ll. The mass
spectrometry parameters were: source temperature 150 C,
desolvation temperature 350 C, capillary voltage 3.5 kV
and 700 l/h of desolvation gas, all other parameters were
compound specific and are detailed in Table 1.
2.8 Analysis of acyl carnitines
200 ll of a mixed standard of eight deuterated carnitines
(Cambridge Isotope Laboratories, Andover, MA, USA)
was diluted into 25 ml of acetonitrile. 200 ll of this solu-
tion was added to one half of the organic fraction from the
original tissue extraction and this was dried down under
nitrogen and derivatised with 3 M HCl in butanol for
15 min at 65 C. The resulting mixture was dried under
nitrogen again and mixed with one half of the sample
remaining from the amino acid analysis. This mixture was
dried a further time and finally reconstituted in 4:1 ace-
tonitrile/0.1 % formic acid in water followed by sonication
to dissolve all species present. Samples were analysed by
LC–MS/MS. The strong mobile phase used for analysis
was acetonitrile with 0.1 % formic acid (B) and the weak
mobile phase was 0.1 % formic acid in water (A). The
analytical UPLC gradient used a Synergi Polar RP phenyl
ether column (100 mm 9 2.1 mm, 2.5 lm) from Phe-
nomenex with 30 % B in 0.1 % formic at 0 min followed
by a linear gradient to 100 % B for 3 min and held at
100 % B for the next 5 min with a further 2 min re-equi-
libration. The total run time was 10 min and the flow rate
was 0.5 ml/min with an injection volume of 2 ll. The mass
spectrometry parameters were: source temperature 150 C,
desolvation temperature 350 C, capillary voltage 3.5 kV
and 500 l/h of desolvation gas, all other parameters were
compound specific and are detailed in Table 1.
2.9 Data analysis
Data were processed using QuanLynx within MassLynx
(version 1.4; Waters Corp., Milford, USA). The data were
imported into SIMCA-P? version 12.0 (Umetrics, Umea˚,
Sweden) for multivariate analysis by principal components
analysis (PCA), partial least squares (PLS) and partial least
squares discriminate analysis (PLS-DA). Data sets were
analysed using PCA for a global visualisation of the
dominant trends in the datasets followed by PLS and PLS-
DA to examine specified clustering or trends. In an ideal
world the supervised approaches would be cross validated
using a train and test routine where 2/3 of the data are used
to train the models produced and the further 1/3 to test the
model robustness. However, this is neither cost effective
nor ethical for many animal studies. Instead, to limit ani-
mal numbers used in the study we used a random
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Table 1 Compound specific mass spectrometry parameters
Compound Ion
mode
Parent mass
(m/z)
Daughter mass
(m/z)
Declustering
potential (V)
Collision energy
(eV)
Column
used
RT (min)
13C5
15N1 glutamate (IS) ? 154.1 89.0 46 21 ZIC
HILIC
5.72
13C5
15N1 glutamate dibutyl ester
(IS)
? 266.2 163.1 25 15 HSS T3 5.86
2-Phosphoglycerate - 184.9 78.8 -35 -20 BEH
amide
2.41
3-Phosphoglycerate ? 187.0 105.0 46 11 BEH
amide
2.44
Acetyl CoA ? 810.0 303.2 81 39 ZIC-
HILIC
5.75
Aconitate - 173.0 85.0 -35 -17 BEH
amide
1.89
Adenine ? 136.0 119.0 126 29 ZIC-
HILIC
0.83
Adenosine ? 268.1 136.1 51 23 ZIC-
HILIC
1.12
Adenosyl methionine ? 399.0 250.1 86 21 ZIC-
HILIC
7.39
ADP ? 428.0 136.0 86 27 ZIC-
HILIC
6.58
Ala butyl ester ? 146.1 44.1 25 15 HSS T3 2.23
AMP ? 348.1 136.0 51 23 ZIC-
HILIC
6.03
Anserine butyl ester ? 297.2 226.2 30 20 HSS T3 1.43
Arg butyl ester ? 231.2 70.1 25 15 HSS T3 1.11
Asn butyl ester ? 188.9 73.8 20 20 HSS T3 1.58
Asp dibutyl ester ? 246.2 144.1 25 15 HSS T3 5.61
ATP ? 508.0 136.0 150 28 ZIC-
HILIC
6.92
Betaine butyl ester ? 173.9 117.9 25 20 HSS T3 2.40
C10 carnitine butyl ester ? 372.3 85.0 35 25 Phenyl
ether
2.30
C10:1 carnitine butyl ester ? 370.3 85.0 35 25 Phenyl
ether
2.12
C10:2 carnitine butyl ester ? 368.3 85.0 35 25 Phenyl
ether
2.00
C12 carnitine butyl ester ? 400.3 85.0 35 25 Phenyl
ether
2.81
C12:1 carnitine butyl ester ? 398.3 85.0 35 25 Phenyl
ether
2.59
C14 carnitine butyl ester ? 428.4 85.0 35 25 Phenyl
ether
3.98
C14:1 carnitine butyl ester ? 426.4 85.0 35 25 Phenyl
ether
3.51
C14:2 carnitine butyl ester ? 424.3 85.0 35 25 Phenyl
ether
3.05
C14-OH carnitine butyl ester ? 444.4 85.0 35 25 Phenyl
ether
3.30
C16 carnitine butyl ester ? 456.4 85.0 35 25 Phenyl
ether
4.47
C16:1 carnitine butyl ester ? 454.4 85.0 35 25 Phenyl
ether
4.25
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Table 1 continued
Compound Ion
mode
Parent mass
(m/z)
Daughter mass
(m/z)
Declustering
potential (V)
Collision energy
(eV)
Column
used
RT (min)
C16:1-OH carnitine butyl ester ? 470.4 85.0 35 25 Phenyl
ether
3.60
C16:2 carnitine butyl ester ? 452.4 85.0 35 25 Phenyl
ether
3.90
C16-OH carnitine butyl ester ? 472.4 85.0 35 25 Phenyl
ether
4.01
C18 carnitine butyl ester ? 484.4 85.0 35 25 Phenyl
ether
4.83
C18:1 carnitine butyl ester ? 482.4 85.0 35 25 Phenyl
ether
4.65
C18:1-OH carnitine butyl ester ? 498.4 85.0 35 25 Phenyl
ether
3.85
C18:2 carnitine butyl ester ? 480.4 85.0 35 25 Phenyl
ether
4.34
C18:2-OH carnitine butyl ester ? 496.4 85.0 35 25 Phenyl
ether
3.55
C18-OH carnitine butyl ester ? 500.4 85.0 35 25 Phenyl
ether
4.15
C2 carnitine butyl ester ? 260.2 85.0 35 25 Phenyl
ether
0.60
C20 carnitine butyl ester ? 512.4 85.0 35 25 Phenyl
ether
5.11
C20:1 carnitine butyl ester ? 510.4 85.0 35 25 Phenyl
ether
4.92
C20:2 carnitine butyl ester ? 508.4 85.0 35 25 Phenyl
ether
4.70
C3 carnitine butyl ester ? 274.2 85.0 35 25 Phenyl
ether
0.75
C4 carnitine butyl ester ? 288.2 85.0 35 25 Phenyl
ether
0.92
C4 dicarboxyl carnitine dibutyl
ester
? 374.3 85.0 35 25 Phenyl
ether
1.43
C5 carnitine butyl ester ? 302.3 85.0 35 25 Phenyl
ether
1.15
C5 dicarboxyl carnitine dibutyl
ester
? 388.3 85.0 35 25 Phenyl
ether
1.67
C5:1 carnitine butyl ester ? 300.2 85.0 35 25 Phenyl
ether
1.00
C5-OH carnitine butyl ester ? 318.2 85.0 35 25 Phenyl
ether
0.64
C6 carnitine butyl ester ? 316.3 85.0 35 25 Phenyl
ether
1.42
C6 dicarboxyl carnitine dibutyl
ester
? 402.3 85.0 35 25 Phenyl
ether
2.82
C8 carnitine butyl ester ? 344.3 85.0 35 25 Phenyl
ether
1.89
C8 dicarboxyl carnitine dibutyl
ester
? 430.4 85.0 35 25 Phenyl
ether
4.02
C8:1 carnitine butyl ester ? 342.3 85.0 35 25 Phenyl
ether
1.87
C8-OH carnitine butyl ester ? 361.3 85.0 35 25 Phenyl
ether
1.20
cAMP ? 330.1 136.1 71 31 ZIC-
HILIC
1.85
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Table 1 continued
Compound Ion
mode
Parent mass
(m/z)
Daughter mass
(m/z)
Declustering
potential (V)
Collision energy
(eV)
Column
used
RT (min)
Carnosine butyl ester ? 283.2 109.9 25 30 HSS T3 1.32
CDP - 402.0 78.9 -25 -80 ZIC-
HILIC
7.14
CDP-choline ? 489.1 184.1 76 47 ZIC-
HILIC
6.85
cGMP ? 346.1 152.1 41 23 ZIC-
HILIC
3.22
Citrate tributyl ester ? 361.2 185 22 15 HSS T3 9.39
Citrulline butyl ester ? 232.1 69.9 20 25 HSS T3 2.00
CMP ? 324.1 112.0 71 17 ZIC-
HILIC
6.34
CTP - 481.9 158.8 -85 -34 ZIC-
HILIC
7.39
Cystine dibutyl ester ? 353.2 73.9 30 35 HSS T3 3.60
Cytidine ? 244.1 112.0 61 15 ZIC-
HILIC
1.73
Cytosine ? 112.0 95.0 136 25 ZIC-
HILIC
1.39
d3 C16 carnitine butyl ester ? 459.4 85.0 35 25 Phenyl
ether
4.47
d3 C2 carnitine butyl ester ? 263.2 85.0 35 25 Phenyl
ether
0.60
d3 C3 carnitine butyl ester ? 277.2 85.0 35 25 Phenyl
ether
0.75
d3 C4 carnitine butyl ester ? 291.2 85.0 35 25 Phenyl
ether
0.92
d3 C8 carnitine butyl ester ? 347.3 85.0 35 25 Phenyl
ether
1.89
d9 C14 carnitine butyl ester ? 437.4 85.0 35 25 Phenyl
ether
3.98
d9 C5 carnitine butyl ester ? 311.3 85.0 35 25 Phenyl
ether
1.15
d9 carnitine butyl ester ? 227.2 85.0 35 25 Phenyl
ether
0.40
Deoxy glucose 6 phosphate (IS) - 243.0 96.9 -62 -20 BEH
Amide
1.95
Dihydroxyacetonephosphate - 168.9 96.9 -65 -12 BEH
amide
2.45
FAD ? 786.1 348.0 191 29 BEH
amide
1.23
Free carnitine butyl ester ? 218.2 85.0 35 25 Phenyl
ether
0.40
Fructose bisphosphate - 339.0 96.9 -30 -24 BEH
amide
3.45
Fumarate butyl ester ? 173.2 173.2 30 5 HSS T3 4.00
GDP ? 444.0 152.0 91 23 ZIC-
HILIC
6.99
Gln butyl ester ? 203.0 83.8 20 20 HSS T3 1.72
Glu dibutyl ester ? 260.2 158.1 25 15 HSS T3 5.86
Glucose 6 phosphate/Fructose 6
phosphate
- 259.0 96.9 -60 -18 BEH
amide
2.35/2.79
Gly butyl ester ? 132.1 76.0 25 15 HSS T3 1.67
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Table 1 continued
Compound Ion
mode
Parent mass
(m/z)
Daughter mass
(m/z)
Declustering
potential (V)
Collision energy
(eV)
Column
used
RT (min)
GMP ? 364.2 152.1 61 19 ZIC-
HILIC
6.68
GSH ? 308.1 179.0 46 17 ZIC-
HILIC
7.49
GSSG ? 613.1 355.0 126 31 ZIC-
HILIC
9.05
GTP ? 523.9 152.0 151 27 ZIC-
HILIC
7.26
Guanine ? 152.0 134.9 66 25 ZIC-
HILIC
1.46
Guanosine ? 284.1 152.1 16 17 ZIC-
HILIC
1.79
His butyl ester ? 212.1 110.1 25 15 HSS T3 0.82
Leu/Ileu butyl ester ? 188.2 86.1 25 15 HSS T3 4.72/4.64
Lys butyl ester ? 203.2 84.1 25 15 HSS T3 0.92
Malonyl CoA ? 854.0 347.1 81 41 ZIC-
HILIC
6.79
Met butyl ester ? 206.1 104.1 25 15 HSS T3 4.04
Methyl Cytosine ? 136.0 109.1 116 25 ZIC-
HILIC
1.21
Methyl Histidine butyl ester ? 226.0 95.8 35 25 HSS T3 0.84
NAD ? 664.0 427.9 111 35 ZIC-
HILIC
5.89
NADP - 741.9 619.8 -65 -22 ZIC-
HILIC
6.92
o-Hydroxy Tyr butyl ester ? 254.1 152.0 26 17 HSS T3 4.20
o-Nitro tyrosine butyl ester ? 283.2 181.0 26 17 HSS T3 4.35
Orn butyl ester ? 189.0 69.9 20 20 HSS T3 0.72
Oxaloacetate - 131.0 87.0 -65 -10 BEH
amide
0.70
Oxo-methionine ? 165.0 105.0 51 7 ZIC-
HILIC
4.75
PCr - 210.0 78.9 -55 -18 BEH
amide
1.89
PEP - 166.9 78.9 -40 -16 BEH
amide
1.95
Phe butyl ester ? 222.2 120.1 25 15 HSS T3 5.17
Pro butyl ester ? 172.1 70.1 25 15 HSS T3 2.74
Pyruvate - 87.0 43.0 -45 -10 BEH
amide
0.60
S-adenosyl-L-homocysteine ? 385.1 136.1 91 23 ZIC-
HILIC
3.91
Ser butyl ester ? 162.1 60.0 25 15 HSS T3 1.69
Succinate - 117.0 73.0 -35 -16 BEH
Amide
1.20
Thr butyl ester ? 176.1 74.1 25 15 HSS T3 2.11
Trp butyl ester ? 261.2 159.1 20 20 HSS T3 5.68
Tyr butyl ester ? 238.1 136.1 25 15 HSS T3 4.01
UDP - 402.9 78.9 -45 -86 ZIC-
HILIC
6.39
UMP ? 325.1 96.9 106 17 ZIC-
HILIC
6.13
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permutation test. In this process the percentage variance
explained (R2) and goodness of fit (Q2) of a model is
compared with models generated where the class mem-
bership has been randomly permuted. If the true model is
significantly better than the random models one has con-
fidence in the overall robustness of the original model.
Student’s t tests and other univariate approaches were
carried out using ExcelTM (Microsoft Corp.), with a sig-
nificance set to p\ 0.05.
3 Results and discussion
To optimise a method for the analysis of a large range of
metabolites a suitable column must be identified to provide
good chromatographic separation, minimize suppression
effects (the ability of one metabolite to reduce the signal
from another metabolite in the mass spectrometer) and aid
the detection of metabolites that might undergo source
fragmentation. If a given compound fragments into its
metabolic precursor in the source of the mass spectrometer
then for a given mass transition several compounds might
be detected. Phosphate species and citric acid cycle inter-
mediates are a particular problem as phosphate and water,
respectively, can be lost when compounds undergo elec-
trospray ionisation (ESI). Figure 1a shows how source
fragmentation can cause a single mass channel to contain
all analytes that break down into the compound investi-
gated. All adenine-containing nucleotides lose their phos-
phate or sugar groups and aconitate and malate lose carbon
dioxide and water, respectively, to yield fumarate during
ionisation. It was therefore necessary to use a chromatog-
raphy approach that separated all of these compounds. The
nucleoside phosphates proved particularly difficult as they
tend to be poorly retained on reverse phases and too well
retained on HILIC phases giving rise to poor peak shape
and reproducibility. Figure 1b shows a comparison of C18,
HILIC silica diol and HILIC zwitterionic (sulfobetaine)
phases for the separation of AMP, ADP and ATP. The
symmetry of the peak shape and the efficient separation in
the ZIC-HILIC analysis showed that this column was ideal
for the analysis of highly polar compounds.
Several of the highly polar analytes such as citric acid
cycle intermediates will only ionise in negative ion mode
in the source of the mass spectrometer. Negative ion mode
often requires the use of alkaline mobile phase additives
such as ammonium hydroxide but ZIC-HILIC cannot be
run at alkaline pH. Thus, a BEH amide HILIC column was
used. The bridged ethyl linkage is stable over a pH range of
2–12 and so is ideal for use with alkaline pH buffers.
Figure 1c shows a range of negative ion mode aqueous
metabolites in an aqueous mouse heart tissue extract
measured on a BEH amide HILIC column. The HILIC
chromatography could separate similar polar compounds,
including isomers such as glucose 6-phosphate and fructose
6-phosphate where the transition 259[ 97 shows three
peaks eluting in order of polarity with the first and last
peaks being fructose 6 phosphate and glucose 6 phosphate,
respectively, with the middle peak most likely being glu-
cose 1 phosphate (not analysed).
Acylcarnitines play a central role in regulating fatty acid
oxidation and mitochondrial metabolism. MS analysis of
acylcarnitine derivatives by butanolic HCl is an established
protocol which benefits from the improved ionisation and
characteristic fragmentation pattern associated with the
derivatisation. Typically, acylcarnitine derivatives are
measured via direct infusion without any chromatography,
but this approach presents problems with robustness and
specificity. Mass transitions are not completely specific to a
given compound and chromatographic separation is
required in order to be sure that a mass transition is mea-
suring the correct compound. Furthermore, with analysing
heart tissue, there is the potential for ion suppression from
phospholipids associated with cell membranes. Thus, we
Table 1 continued
Compound Ion
mode
Parent mass
(m/z)
Daughter mass
(m/z)
Declustering
potential (V)
Collision energy
(eV)
Column
used
RT (min)
Uracil ? 112.9 70.1 111 23 ZIC-
HILIC
0.91
Uridine ? 245.1 112.9 81 17 ZIC-
HILIC
1.17
UTP - 482.9 158.9 -45 -34 ZIC-
HILIC
6.93
Val butyl ester ? 174.2 72.1 25 15 HSS T3 3.80
a ketoglutarate - 145.0 101.0 -40 -12 BEH
Amide
1.35
The table shows ionisation mode, mass transitions (parent and daughter masses) and retention times as well as declustering potentials and the
collision energies required for each analyte
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Fig. 1 Optimisation of the LC–
MS/MS method for studying
cardiac metabolism. a Fumarate
and adenine transitions using
polar reverse phase
chromatography for fumarate
(Polar RP (5 9 2.1 mm,
2.5 lm), Phenomenex) and
HILIC chromatography for
adenine from aqueous heart
tissue extracts. b Three UV
chromatograms of a mixed
standard of AMP, ADP and
ATP at 10 lM showing
different approaches to the
separation of highly polar
analytes. The C18 method used
a C18 column (100 9 2.1,
1.7 lm; HSS T3 column,
Waters) using an isocratic 5 min
gradient of 5 % acetonitrile in
0.1 % formic acid at a flow rate
of 400 ll/min. The sulfobetaine
HILIC method used a ZIC-
HILIC column (100 9 2.1,
3.5 lm; Merck) and an isocratic
gradient of 30 % 100 mM
NH4OAc in acetonitrile at a
flow rate of 200 ll/min. The
silica diol HILIC method used a
HILIC column (100 9 2.1,
2.5 lm, Phenomenex) and an
isocratic gradient of 30 %
20 mM NH4OAc in acetonitrile
at a flow rate of 300 ll/min. All
analyses were measured at
k = 260 nm. c A series of
extracted ion chromatograms
showing negative ion mode
compounds in an aqueous
extract of a mouse heart tissue
sample separated on a BEH
amide column. (100 9 2.1 mm,
1.7 lm; Waters Ltd.)
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developed a chromatographic method to separate the
acylcarnitines following derivatisation (Fig. 2a).
To test linearity ten matrix-matched internal standard
replicates (i.e. labelled standards in a heart tissue extract)
were injected alongside 10 standard solutions and found to
have average coefficients of variation of 12.3 and 6.3 %,
respectively. Linearity was investigated in non matrix-
matched solutions using free carnitine, acetyl carnitine and
palmitoyl carnitine standards with the appropriate deuter-
ated analogue as internal standard for each compound. Free
carnitine and acetyl carnitine were found to be linear in the
range 5 nM to 20 lM (R2 = 0.971, 0.97, respectively),
whereas palmitoyl carnitine was found to be linear in the
range 50 nM to 20 lM (R2 = 0.98).
As the butylation derivatisation protocol forms an ester
with the carboxylate moiety it can be used to form
derivatives of any carboxylic acid if they are sufficiently
stable to survive the derivatisation process including amino
acids and stable oxoacids (e.g. citric acid cycle interme-
diates). This derivatisation process also aids chromato-
graphic separation and the detection of low concentration
metabolites. The length of derivatisation using the
butanolic HCl protocol is important, as species such as
glutamic acid and citric acid can be derivatised several
times due to the presence of more than one carboxyl group
and species such as glutamine and asparagine contain acid
labile amide moieties that can be transformed to butyl
esters on reaction with butanolic HCl. Mixtures of stan-
dards were dried and treated with 200 ll of butanolic HCl
for 15, 30, 45 and 60 min. The time of 15 min was found to
be the best as significant amounts of citrate were deriva-
tised 3 times whereas less than 10 % of asparagine and
glutamine was broken down into aspartic acid and glutamic
acid butyl esters (data not shown).
The derivatisation method for amino acids and acyl
carnitines used in the present study has a venerable history,
having been developed for the rapid screening of inborn
errors of metabolism nearly 20 years ago (Chance et al.
1996). While it requires extra sample preparation it is a
very robust method, showing almost no retention time drift
over analytical runs of hundreds of samples and requiring a
generic processing method to process samples across
numerous analytical runs. Furthermore, the added sensi-
tivity afforded by the derivatisation was necessary on the
triple quadrapole we used in the current manuscript for
lower concentration metabolites, particularly the species
produced from reactions with ROS (e.g. oxo-methionine,
o-hydroxy-tyrosine and o-nitro-tyrosine).
Having established a suitable gradient for the analysis of
29 amino acids and two oxo-acids (with particular care
being taken to ensure that isomeric compounds such as
leucine and isoleucine were separated although it was not
possible to separate the methyl histidine amino acids)
experiments were carried out to determine the robustness
of the assay in a biological matrix and linearity of the
compounds investigated. Ten replicates of [U–13C, 15N]
glutamic acid and [U–13C, 15N] proline spiked samples
were extracted with human heart tissue and compared to
non-matrix-matched standards. The coefficients of varia-
tion for the matrix matched injections were 7.1 and 9.5 %
for glutamate and proline, respectively, whereas the non-
matrix matched injections showed CVs of 9.0 and 8.5 %
for labelled glutamate and proline. All compounds behaved
linearly across a physiologically relevant range of con-
centrations (Fig. 2c; Supplementary Fig. 1a).
The methods detailed above were applied to the analysis
heart extracts from the Lmna knockout mouse, comparing
animals at 2 and 5 weeks of age. A total of 39 metabolites
were above the level of detection in both negative and
positive ion mode using HILIC chromatography and the
dataset was analysed by PLS-DA. While there was no
discrimination between the 2 week old animals, the 5 week
homozygous mice were readily discriminated from the
5 week wildtype and heterozygous mice (Fig. 3a). PLS-
DA component 1 was associated with the difference
between 2 and 5 week old animals whereas the second
PLS-DA component described the genetic variation at
week 5. To specifically probe genotype changes a PLS-DA
model was built that compared the wild type mice and
heterozygous mice with the homozygous group at the
5 week time point (Fig. 3b; Q2 = 78 %) and passed cross-
validation (Fig. 3c). Metabolic changes are summarised in
an S-plot in Fig. 3d. These changes were confirmed by
univariate statistics (Fig. 3e) and associated with increases
in the concentrations of uracil, glutathione (both reduced
and oxidized), cAMP and fructose bisphosphate and
decreases in the concentration of cytidine, uridine, GDP,
acetyl-CoA, adenosine, aconitate and fumarate in the
homozygous mouse. However, examining the heterozy-
gous and wildtype samples from 40 week old mice no
significant PLS-DA model could be built (data not shown).
While the data used in this study were processed in a semi-
quantitative manner, normalising peak areas to a labelled
standard (8 deuterated carnitine species for the carnitine
assay, deoxy glucose 6 phosphate for the glycolytic inter-
mediates and [U–13C, 15N] glutamate for all other com-
pounds with the butylated analogue of this internal
standard being used for the normalisation of the amino
acids) but not calculating specific concentrations, the
methods we detail could have been made quantitative as
they rely on the isotope dilution approach, and we were
only impeded in this by the lack of availability of cheap
isotopically labelled standards for metabolites.
The laminopathy model was further investigated using
the amino acid analytical method described above. The
same pattern was observed as for the HILIC mode in the
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week 2 and week 5 old mice, where one multivariate
component discriminated 2 and 5 week old animals, and
the other described the metabolic changes due to the
genetic modification (Fig. 4a). Wildtype and heterozygous
animals were treated as one group and compared to the
homozygous mice using PLS-DA yielding the S-plot
shown in Fig. 4b. The separation was associated with rel-
ative increases in a range of amino acids in the heart tissue
of homozygous animals including alanine, serine, glycine,
asparagine, proline, valine, threonine, leucine, methionine,
phenylalanine and tyrosine and decreases in the concen-
tration of arginine, citrulline, lysine and hydroxyl-tyrosine.
The PLS-DA model passed cross-validation by random
permutation. Extracts from the week 40 old animals could
not be readily distinguished using PLS-DA and the model
had a poor Q2 (model parameters R2X = 36 %,
R2Y = 73 %, Q2 = -21 %; data not shown). Univariate
analysis was applied to the metabolites driving the changes
Fig. 2 LC–MS/MS analysis of
butylated acyl carnitines and
amino acids. a Four extracted
ion chromatograms of a heart
tissue extract measured using a
Phenomenex Synergi Polar RP
column. This
figure demonstrates the need for
specificity when conducting
acyl carnitine analysis with
significant impurities detected
in two of the channels. b Four
extracted ion chromatograms of
a heart tissue extract measured
using a Waters HSS T3 column
showing the requirement for
chromatographic separation in
order to separate isobaric or
near isobaric compounds. c A
linearity graph showing the
response of nine amino acids
and fumarate over the range
10 nM to 500 lM. [U–13C, 15N]
glutamate was used as an
internal standard
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Fig. 3 a Scores plot comparing
profiles of chromatograms from
HILIC mode aqueous analysis
of tissue from wildtype,
heterozygous and homozygous
LMNA mouse hearts at 2 and
5 weeks (R2X = 31 %,
R2Y = 41 %, Q2 = 20 %).
b Scores plot comparing profiles
of chromatograms from HILIC
mode aqueous analysis of tissue
from wildtype and heterozygous
mice with homozygous
laminopathic mouse hearts at
the 5 week time point
(R2X = 41 %, R2Y = 93 %,
Q2 = 78 %). c Validation plot
showing how the values of Q2
and R2 are affected by 100
random class assignments.
Positive slopes of the resulting
best fit lines indicate that
random class assignment has
failed to produce as significant a
model as the original model.
d An S-plot showing the
contribution of the various
metabolites measured to the
separation between the two
classes in terms of HILIC mode
profiles. Metabolites in the top
right hand corner are relatively
increased in the wild type and
heterozygous group and those in
the bottom left hand corner are
decreased. FBP fructose-1,6-
bisphophate, cAMP cyclic
AMP, GSH reduced glutathione,
GSSG oxidized glutathione, Urc
uracil, Gua guanine, PCr
phosphocreatine, Guas
guanosine, Oxalo oxaloacetate,
Pyr pyruvate, Cyts cytosine,
PEP phosphenol pyruvate, G6P
glucose-6-phosphate, F6P
fructose-6-phosphate, Mal
malate, Cit citrate, Icit
isocitrate, Oxo-gua oxo-
guanine, Aco aconitate, Cytd
cytidine, Fum fumarate, Urd
uridine, Ads adenosine.
e Histograms summarising the
significant metabolic changes
between the homozygous and
the heterozygous and wild type
mice when analysed for HILIC
mode compounds. Standard
error bars are shown and
Student’s t tests have been
carried out (*p\ 0.05,
**p\ 0.01, ***p\ 0.001,
****p\ 0.0001)
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summarised in the PLS-DA plots, demonstrating that a
wide range of amino acids changed in concentration, with
the majority of changes being associated with relative
increases in the concentration of amino acids (Fig. 4c).
The tissue extracts were further analysed for acyl car-
nitines using the method described above. PLS-DA again
discriminated tissue from 2 and 5 week-old animals, with
one component describing the variation according to age
and the other the genetic variation where the heterozygous
and wildtype animals co-cluster with the homozygous
animals clustering separately. Direct PLS-DA comparison
of these two groups for the 5-week old animals produced a
model with Q2 = 72 %, and analysis of the corresponding
loadings plot showed that the separation was due a total
decrease in carnitine concentrations in the homozygous
mice relative to the combined control group (wildtype and
heterozygous animals considered as a single group) and
this was confirmed by univariate analysis (Fig. 4d). The
same approach was applied to the week 40-old animals, but
no multivariate model could be built that discriminated the
two groups (data not shown).
Several groups in the field of metabolomics have
attempted to develop single column methods to analyse the
largest proportion of the aqueous metabolome in a single
assay, including Luo et al. (2013) and Bajad et al. (2006)
where bacterial extracts have had up to 20 % of their
aqueous metabolome profiled. However, these approaches,
because of their non-targeted nature, where the method
represents a compromise across many classes of com-
pounds, while convenient, do not produce the best quality
data in terms of limits of detection and reproducibility for a
large proportion of their analytical targets. Furthermore, for
some species, these approaches have failed to measure the
desired compounds since full chromatographic resolution is
Fig. 3 continued
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Fig. 4 a PLS-DA scores plot
comparing the profile of amino
acids in tissue extracts from
wildtype, heterozygous and
homozygous laminopathic
mouse hearts from mice at 2 and
5 weeks (model parameters
R2X = 82 %, R2Y = 63 %,
Q2 = 43 %). b An S-plot
showing the contribution of the
various metabolites measured in
heart tissue to the separation
between homozygous and the
control group (wildtype and
heterozygous animals).
Metabolites in the top right hand
corner are relatively increased
in the wild type and
heterozygous group and those in
the bottom left hand corner are
decreased. cit citrulline, arg
arginine, lys lysine, his
histidine, OHtyr hydroxy-
tyrosine, gln glutamine, asp
aspartate, glu glutamate, ans
anserine, leu leucine, tyr
tyrosine, gly glycine, Ile
isoleucine, val valine, trp
tryptophan, pro proline, asn
asparagine, phe phenylalanine,
orn ornithine, car carnosine, ala
alanine, ser serine, Me-His
methyl histidine, met
methionine, thr threonine.
c Histograms summarising the
significant metabolic changes in
amino acid profiles between the
homozygous and heterozygous
5-week old laminopathic mouse
hearts. Standard error bars are
shown for Student’s t tests
(*p\ 0.05, **p\ 0.01,
***p\ 0.001,
****p\ 0.0001). d Histogram
showing changes in total
carnitine concentrations on
comparison of mouse heart
tissue from wildtype,
heterozygous and homozygous
laminopathic mice. Standard
error bars for Student’s t tests
are shown. (*p\ 0.05,
**p\ 0.01, ***p\ 0.001,
****p\ 0.0001)
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sometimes necessary in cases where ESI source fragmen-
tation degrades analytes into metabolic precursors. We
decided to sub-divide analytes into a small number of
targeted assays to represent a wide proportion of cardiac
metabolism, allowing for better sensitivity, reproducibility,
quantification and reliability across this assay.
Several analytes of interest are too polar to be well
retained and separated using a reverse phase approach and
so a HILIC method was used. HILIC uses largely organic
mobile phases with aqueous buffers (up to about 50 % in the
eluent) as the strong solvent. An aqueous layer is formed on
the surface of the silica and this layer allows retention of the
analytes. The interaction between mobile phase and analyte
is therefore weak enough to allow relatively unsta-
ble molecules such as ATP and other metabolites with a
labile phosphate to be analysed. Most HILIC columns use a
silica diol functionalisation to trap this aqueous layer on the
silica particles. This was found to be unsatisfactory in the
present study as it led to significant peak tailing. Zwitteri-
onic stationary phases, as occur in ZIC-HILIC columns,
were found to be more desirable as they do not exhibit
tailing of more polar compounds. However, the ZIC-HILIC
column used in the paper was highly susceptible to ionic
contamination from the samples, causing peak tailing over
continued use with sometimes as few as 100 injections of
heart tissue. While Solid Phase Extraction clean-up of
contaminants or column regeneration could have been
employed both increase sample preparation times and nei-
ther were favourable in our pilot studies.
The application of metabolomics to studying either
HCM or DCM has been relatively rare in the literature to
date, despite a compelling case being made for the appli-
cation of systems medicine approaches to these diseases,
particularly for treatment (Piran et al. 2012). Alexander
et al. (2011) used a combination of GC–MS and LC–MS to
profile metabolites in the blood plasma of individuals with
primary DCM, with patients with DCM being associated
with decreased concentrations of steroids, glutamine,
threonine and histidine, while there were increased con-
centrations of citric acid cycle and b-oxidation intermedi-
ates. In particular, they reported a reduction in glutamine
and increased concentrations of 3-methylhistidine and
prolylhydroxyproline, suggestive of increased myofibrillar
and collagen degradation in DCM patients. In the present
study, while glutamine did not change in the heart of the
LMNA-/- mouse, there were increases in both proline and
methyl-histidine in the present study, along with a net
increase in many amino acids, suggestive of increased
myofibrillar and collagen degradation. There was also a
decrease in citric acid cycle intermediates and carnitine
derivatives in the heart tissue of the LMNA-/- mice which
suggests that in the study by Alexander et al. (2011) the
increased blood plasma concentrations of citric acid cycle
and b-oxidation intermediates is associated with loss from
heart and muscle tissue, as a result of cellular stress and
disruption of the cell membrane stability arising from the
laminopathy. Similarly, Maekawa et al. (2013) observed
reduced concentrations of citric acid cycle, glycolytic and
pentose phosphate pathway intermediates in J2N-k car-
diomyopathic hamsters, underlying the reduction in energy
substrates in the DCM heart. While Maekawa et al.
reported a mild decrease in glutathione in their model, and
we detected a net increase in glutathione these could rep-
resent a response to ROS production in both models, with
the net increase in the LMNA-/- mouse suggesting that the
heart has adaptively upregulated the production of the anti-
oxidant to counter ROS exposure.
Examining heart tissue from patients with either chronic
ischaemic (ISCM) or idiopathic dilated cardiomyopathy
(IDCM) by metabolomics and proteomics, Klawitter et al.
(2013) also observed a decrease in the concentration of
citric acid cycle intermediates, as well as glycolysis and the
malate-aspartate shuttle. While ketone bodies were
increased in ISCM compared with IDCM, the metabo-
lomics results of both our study and Klawitter et al. (2013)
demonstrate profound metabolic deficits associated with
DCM. Intriguingly, Klawitter et al. also highlighted chan-
ges in the phosphorylation of AKT in their proteomic
dataset. As AKT is central to muscle biogenesis and protein
synthesis, the changes may reflect increased protein turn-
over in DCM and explain the relative increase in the
majority of amino acids detected in our present study.
Furthermore, Marin˜o et al. (2014) made the interesting
connection between maladaptive autophagy, cardiac
remodelling and DCM that could explain the large number
of changes in amino acid metabolism following cardiac
remodelling associated with DCM.
The assays presented here could equally be applied in
the clinical setting to monitor disease progression in those
with cardiac disease. Although we primarily developed the
assays to investigate how metabolism is perturbed in a
mouse model of DCM, the identified metabolic changes
could be used together as a fingerprint of the disease pro-
cess to monitor disease progression or even treatment
efficacy. A combination of metabolic changes will proba-
bly be more robust than single metabolic ‘biomarkers’ as
they better represent the complex perturbations induced
during human disease. It should be noted that triple
quadrupoles, like the one used in the present study, are
found in many hospitals, particularly for inborn error
screening, and thus much of the infrastructure required to
extend this approach into the clinic is already available.
Finally, we also made the distinction between open and
targeted metabolomic assays in the introduction, as well as
the pros and cons between the two approaches. However, it
should be stated that the discrimination is becoming
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blurred. With the advent of in silico approaches for
reconstructing tandem mass spectrometry approaches such
as MSE (where E is the collision energy) (Zhang et al.
2009) and SWATH-MS (where a swath is cycle through
consecutive precursor isolation windows) (Gillet et al.
2012) it is now possible to reconstruct such targeted
analyses from untargeted approaches, and indeed detect
knowns and unknowns in a simultaneous analysis.
4 Concluding remarks
In conclusion, we present a quantitative method for cardiac
metabolomics which covers the core metabolism of the
heart, and demonstrate its applicability in terms of profiling
a mouse model of DCM. The assay demonstrates that the
LMNA-/- mouse heart has decreased metabolites associ-
ated with the citric acid cycle and b-oxidation, but increased
turnover of proteins and responses to oxidative stress.
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